Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by THOMAS LLOYD and THOMAS LLOYD.
THOMAS LLOYD
Connection Strength
20.678
THOMAS LLOYD
  1. Loss of TDP-43 Splicing Repression Occurs in Myonuclei of Inclusion Body Myositis Patients. Ann Neurol. 2025 Apr; 97(4):629-641.
    View in: PubMed
    Score: 0.949
  2. Disrupted endoplasmic reticulum-mediated autophagosomal biogenesis in a Drosophila model of C9-ALS-FTD. Autophagy. 2024 01; 20(1):94-113.
    View in: PubMed
    Score: 0.863
  3. Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis. Neurology. 2023 03 28; 100(13):e1406-e1417.
    View in: PubMed
    Score: 0.828
  4. The role of autophagic kinases in regulation of axonal function. Front Cell Neurosci. 2022; 16:996593.
    View in: PubMed
    Score: 0.810
  5. Nucleoporins are degraded via upregulation of ESCRT-III/Vps4 complex in Drosophila models of C9-ALS/FTD. Cell Rep. 2022 09 20; 40(12):111379.
    View in: PubMed
    Score: 0.809
  6. Defective axonal transport of endo-lysosomes and dense core vesicles in a Drosophila model of C9-ALS/FTD. Traffic. 2022 09; 23(9):430-441.
    View in: PubMed
    Score: 0.804
  7. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med. 2022 01 19; 14(628):eabi9196.
    View in: PubMed
    Score: 0.772
  8. TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. Elife. 2020 12 10; 9.
    View in: PubMed
    Score: 0.715
  9. Secondary Causes of Myositis. Curr Treat Options Neurol. 2020; 22(11):38.
    View in: PubMed
    Score: 0.706
  10. TRPV4 disrupts mitochondrial transport and causes axonal degeneration via a CaMKII-dependent elevation of intracellular Ca2. Nat Commun. 2020 05 29; 11(1):2679.
    View in: PubMed
    Score: 0.689
  11. How can an understanding of the C9orf72 gene translate into amyotrophic lateral sclerosis therapies? Expert Rev Neurother. 2019 10; 19(10):895-897.
    View in: PubMed
    Score: 0.647
  12. Drosophila models of amyotrophic lateral sclerosis with defects in RNA metabolism. Brain Res. 2018 08 15; 1693(Pt A):109-120.
    View in: PubMed
    Score: 0.598
  13. Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell. 2018 05 03; 173(4):958-971.e17.
    View in: PubMed
    Score: 0.594
  14. FUS causes synaptic hyperexcitability in Drosophila dendritic arborization neurons. Brain Res. 2018 08 15; 1693(Pt A):55-66.
    View in: PubMed
    Score: 0.594
  15. New Developments in the Genetics of Inclusion Body Myositis. Curr Rheumatol Rep. 2018 04 02; 20(5):26.
    View in: PubMed
    Score: 0.594
  16. Fifteen-year longitudinal follow-up of a patient with severe early-onset Charcot-Marie-Tooth disease type 2A. Muscle Nerve. 2018 05; 57(5):E126-E128.
    View in: PubMed
    Score: 0.586
  17. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology. 2017 Apr 11; 88(15):1454-1460.
    View in: PubMed
    Score: 0.551
  18. A Case of Morvan Syndrome Mimicking Amyotrophic Lateral Sclerosis With Frontotemporal Dementia. J Clin Neuromuscul Dis. 2016 Jun; 17(4):207-11.
    View in: PubMed
    Score: 0.523
  19. Whole-body MR neurography: Prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease. J Magn Reson Imaging. 2016 12; 44(6):1513-1521.
    View in: PubMed
    Score: 0.519
  20. Nucleocytoplasmic transport in C9orf72-mediated ALS/FTD. Nucleus. 2016 Apr 25; 7(2):132-7.
    View in: PubMed
    Score: 0.519
  21. FIG4 regulates lysosome membrane homeostasis independent of phosphatase function. Hum Mol Genet. 2016 Feb 15; 25(4):681-92.
    View in: PubMed
    Score: 0.506
  22. Drosophila models of neurologic disease. Exp Neurol. 2015 Dec; 274(Pt A):1-3.
    View in: PubMed
    Score: 0.505
  23. Laing distal myopathy pathologically resembling inclusion body myositis. Ann Clin Transl Neurol. 2014 Dec; 1(12):1053-8.
    View in: PubMed
    Score: 0.469
  24. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014 Jul 29; 83(5):426-33.
    View in: PubMed
    Score: 0.457
  25. The ALS gene FUS regulates synaptic transmission at the Drosophila neuromuscular junction. Hum Mol Genet. 2014 Jul 15; 23(14):3810-22.
    View in: PubMed
    Score: 0.447
  26. Peripheral neuropathy: clinical and electrophysiological considerations. Neuroimaging Clin N Am. 2014 Feb; 24(1):49-65.
    View in: PubMed
    Score: 0.424
  27. Axonal transport disruption in peripheral nerve disease: From Jack's discoveries as a resident to recent contributions. J Peripher Nerv Syst. 2012 Dec; 17 Suppl 3:46-51.
    View in: PubMed
    Score: 0.410
  28. The p150(Glued) CAP-Gly domain regulates initiation of retrograde transport at synaptic termini. Neuron. 2012 Apr 26; 74(2):344-60.
    View in: PubMed
    Score: 0.393
  29. Novel therapeutic approaches for inclusion body myositis. Curr Opin Rheumatol. 2010 Nov; 22(6):658-64.
    View in: PubMed
    Score: 0.355
  30. Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy. Neurol Genet. 2025 Aug; 11(4):e200265.
    View in: PubMed
    Score: 0.061
  31. Activated Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells. medRxiv. 2025 Jun 05.
    View in: PubMed
    Score: 0.061
  32. Characterizing local antibody responses in the muscle of inclusion body myositis patients. J Autoimmun. 2025 Jun; 154:103437.
    View in: PubMed
    Score: 0.061
  33. Emerging mechanisms and therapeutics in inflammatory muscle diseases. Trends Pharmacol Sci. 2025 03; 46(3):249-263.
    View in: PubMed
    Score: 0.060
  34. Seeding-competent TDP-43 persists in human patient and mouse muscle. Sci Transl Med. 2024 11 27; 16(775):eadp5730.
    View in: PubMed
    Score: 0.059
  35. Pathological autoantibody internalisation in myositis. Ann Rheum Dis. 2024 10 21; 83(11):1549-1560.
    View in: PubMed
    Score: 0.058
  36. Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis. Nat Aging. 2024 Jul; 4(7):969-983.
    View in: PubMed
    Score: 0.057
  37. Seeding competent TDP-43 persists in human patient and mouse muscle. bioRxiv. 2024 Apr 04.
    View in: PubMed
    Score: 0.056
  38. Correction to: Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis. J Neurol. 2024 Apr; 271(4):2147-2148.
    View in: PubMed
    Score: 0.056
  39. Disrupted nuclear import of cell cycle proteins in Huntington's/PolyQ disease causes neurodevelopment defects in cellular and Drosophila model. Heliyon. 2024 Feb 29; 10(4):e26393.
    View in: PubMed
    Score: 0.056
  40. Pathogenic autoantibody internalization in myositis. medRxiv. 2024 Jan 17.
    View in: PubMed
    Score: 0.055
  41. Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants. Brain. 2023 10 03; 146(10):4336-4349.
    View in: PubMed
    Score: 0.054
  42. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 10; 22(10):900-911.
    View in: PubMed
    Score: 0.054
  43. Identification of Unique microRNA Profiles in Different Types of Idiopathic Inflammatory Myopathy. Cells. 2023 09 02; 12(17).
    View in: PubMed
    Score: 0.054
  44. The pattern of MHC class I expression in muscle biopsies from patients with myositis and other neuromuscular disorders. Rheumatology (Oxford). 2023 09 01; 62(9):3156-3160.
    View in: PubMed
    Score: 0.054
  45. Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis. J Neurol. 2023 Dec; 270(12):5849-5865.
    View in: PubMed
    Score: 0.054
  46. Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies. Ann Rheum Dis. 2023 08; 82(8):1091-1097.
    View in: PubMed
    Score: 0.053
  47. Provisional practice recommendation for the management of myopathy in VCP-associated multisystem proteinopathy. Ann Clin Transl Neurol. 2023 05; 10(5):686-695.
    View in: PubMed
    Score: 0.053
  48. c-Jun N-Terminal Kinase Promotes Stress Granule Assembly and Neurodegeneration in C9orf72-Mediated ALS and FTD. J Neurosci. 2023 04 26; 43(17):3186-3197.
    View in: PubMed
    Score: 0.052
  49. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Ann Rheum Dis. 2023 06; 82(6):829-836.
    View in: PubMed
    Score: 0.052
  50. Coordinated local RNA overexpression of complement induced by interferon gamma in myositis. Sci Rep. 2023 02 04; 13(1):2038.
    View in: PubMed
    Score: 0.052
  51. Current status of clinical outcome measures in inclusion body myositis: a systematised review. Clin Exp Rheumatol. 2023 Mar; 41(2):370-378.
    View in: PubMed
    Score: 0.052
  52. Disease Progression in Charcot-Marie-Tooth Disease Related to MPZ Mutations: A Longitudinal Study. Ann Neurol. 2023 03; 93(3):563-576.
    View in: PubMed
    Score: 0.051
  53. Poly(ADP-ribose) promotes toxicity of C9ORF72 arginine-rich dipeptide repeat proteins. Sci Transl Med. 2022 09 14; 14(662):eabq3215.
    View in: PubMed
    Score: 0.051
  54. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1? autoantibodies. Ann Rheum Dis. 2023 Feb; 82(2):246-252.
    View in: PubMed
    Score: 0.050
  55. Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses. Immunity. 2022 06 14; 55(6):1051-1066.e4.
    View in: PubMed
    Score: 0.049
  56. Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. Nat Commun. 2022 04 28; 13(1):2306.
    View in: PubMed
    Score: 0.049
  57. Human pluripotent stem cell-derived myogenic progenitors undergo maturation to quiescent satellite cells upon engraftment. Cell Stem Cell. 2022 04 07; 29(4):610-619.e5.
    View in: PubMed
    Score: 0.049
  58. Prevalence of avascular necrosis in idiopathic inflammatory myopathies: a single-centre experience. Rheumatology (Oxford). 2022 03 02; 61(3):936-942.
    View in: PubMed
    Score: 0.049
  59. Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis. Ann Neurol. 2022 03; 91(3):317-328.
    View in: PubMed
    Score: 0.048
  60. Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. Clin Infect Dis. 2022 02 11; 74(3):427-436.
    View in: PubMed
    Score: 0.048
  61. Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis Rheumatol. 2022 02; 74(2):358-364.
    View in: PubMed
    Score: 0.048
  62. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. iScience. 2021 Nov 19; 24(11):103221.
    View in: PubMed
    Score: 0.047
  63. Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases. J Neurol Neurosurg Psychiatry. 2021 11; 92(11):1186-1196.
    View in: PubMed
    Score: 0.046
  64. The phenotype of myositis patients with anti-Ku autoantibodies. Semin Arthritis Rheum. 2021 08; 51(4):728-734.
    View in: PubMed
    Score: 0.046
  65. UPF1 reduces C9orf72 HRE-induced neurotoxicity in the absence of nonsense-mediated decay dysfunction. Cell Rep. 2021 03 30; 34(13):108925.
    View in: PubMed
    Score: 0.046
  66. Neuropathy-causing TRPV4 mutations disrupt TRPV4-RhoA interactions and impair neurite extension. Nat Commun. 2021 03 04; 12(1):1444.
    View in: PubMed
    Score: 0.045
  67. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 03 23; 96(12):e1595-e1607.
    View in: PubMed
    Score: 0.045
  68. RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES. medRxiv. 2021 Feb 05.
    View in: PubMed
    Score: 0.045
  69. p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). Cell. 2021 02 04; 184(3):689-708.e20.
    View in: PubMed
    Score: 0.045
  70. Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. Brain. 2020 12 01; 143(12):3589-3602.
    View in: PubMed
    Score: 0.045
  71. Ultra-efficient sequencing of T Cell receptor repertoires reveals shared responses in muscle from patients with Myositis. EBioMedicine. 2020 Sep; 59:102972.
    View in: PubMed
    Score: 0.044
  72. Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2021 Mar-Apr; 39(2):351-356.
    View in: PubMed
    Score: 0.044
  73. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis. 2020 09; 79(9):1234-1242.
    View in: PubMed
    Score: 0.043
  74. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology. 2020 03 03; 94(9):e884-e896.
    View in: PubMed
    Score: 0.042
  75. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019 09 17; 93(12):e1193-e1204.
    View in: PubMed
    Score: 0.041
  76. Variation in SIPA1L2 is correlated with phenotype modification in Charcot- Marie- Tooth disease type 1A. Ann Neurol. 2019 03; 85(3):316-330.
    View in: PubMed
    Score: 0.040
  77. Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study. J Neuromuscul Dis. 2019; 6(2):201-211.
    View in: PubMed
    Score: 0.039
  78. Muscle endurance deficits in myositis patients despite normal manual muscle testing scores. Muscle Nerve. 2019 01; 59(1):70-75.
    View in: PubMed
    Score: 0.039
  79. Heterogeneity in gut microbiota drive polyphenol metabolism that influences a-synuclein misfolding and toxicity. J Nutr Biochem. 2019 02; 64:170-181.
    View in: PubMed
    Score: 0.039
  80. TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. Nature. 2018 11; 563(7732):508-513.
    View in: PubMed
    Score: 0.039
  81. Internal grant review to increase grant funding for junior investigators. Ann Neurol. 2017 10; 82(4):497-502.
    View in: PubMed
    Score: 0.036
  82. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017 05 01; 56(5):787-794.
    View in: PubMed
    Score: 0.035
  83. Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron. 2017 Apr 05; 94(1):93-107.e6.
    View in: PubMed
    Score: 0.035
  84. Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis. Acta Neuropathol Commun. 2017 03 22; 5(1):24.
    View in: PubMed
    Score: 0.035
  85. Tdp-43 cryptic exons are highly variable between cell types. Mol Neurodegener. 2017 02 02; 12(1):13.
    View in: PubMed
    Score: 0.034
  86. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol. 2017 Feb; 81(2):227-239.
    View in: PubMed
    Score: 0.034
  87. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2017 04; 76(4):681-687.
    View in: PubMed
    Score: 0.033
  88. Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. J Neuromuscul Dis. 2016 03 03; 3(1):67-75.
    View in: PubMed
    Score: 0.032
  89. Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e172.
    View in: PubMed
    Score: 0.031
  90. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015 Sep 03; 525(7567):56-61.
    View in: PubMed
    Score: 0.031
  91. Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene. Brain. 2015 Nov; 138(Pt 11):3180-92.
    View in: PubMed
    Score: 0.031
  92. A TRPV channel in Drosophila motor neurons regulates presynaptic resting Ca2+ levels, synapse growth, and synaptic transmission. Neuron. 2014 Nov 19; 84(4):764-77.
    View in: PubMed
    Score: 0.029
  93. Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy. Am J Hum Genet. 2014 Sep 04; 95(3):332-9.
    View in: PubMed
    Score: 0.029
  94. WIDE AWAKE mediates the circadian timing of sleep onset. Neuron. 2014 Apr 02; 82(1):151-66.
    View in: PubMed
    Score: 0.028
  95. Cbl-associated protein regulates assembly and function of two tension-sensing structures in Drosophila. Development. 2013 Feb 01; 140(3):627-38.
    View in: PubMed
    Score: 0.026
  96. Sciatic nerve tumor and tumor-like lesions - uncommon pathologies. Skeletal Radiol. 2012 Jul; 41(7):763-74.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.